## Marry M Van Den Heuvel-Eibrink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6109338/publications.pdf

Version: 2024-02-01



Marry M Van Den

#	Article	IF	CITATIONS
1	The MLL recombinome of acute leukemias in 2017. Leukemia, 2018, 32, 273-284.	7.2	527
2	Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nature Genetics, 2010, 42, 794-800.	21.4	308
3	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.	1.4	304
4	Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nature Biotechnology, 2019, 37, 303-313.	17.5	301
5	Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. Journal of Clinical Oncology, 2015, 33, 2999-3007.	1.6	281
6	Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol. Nature Reviews Urology, 2017, 14, 743-752.	3.8	249
7	Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncology, The, 2009, 10, 957-966.	10.7	216
8	An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 2020, 11, 1310.	12.8	183
9	Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration With the PanCareSurFup Consortium Journal of Clinical Oncology, 2016, 34, 3440-3450	1.6	173
10	Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatric Blood and Cancer, 2008, 50, 1130-1134.	1.5	151
11	Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Review. Journal of Clinical Oncology, 2018, 36, 2169-2180.	1.6	137
12	Prospective Study on Incidence, Risk Factors, and Long-Term Outcome of Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2011, 29, 4143-4150.	1.6	128
13	Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: A report of the SIOP renal tumour study group. Pediatric Blood and Cancer, 2011, 56, 733-737.	1.5	125
14	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study. Journal of Clinical Oncology, 2016, 34, 3195-3203.	1.6	105
15	Childhood cancer survivor cohorts in Europe. Acta Oncológica, 2015, 54, 655-668.	1.8	97
16	CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Annals of Hematology, 2007, 86, 329-337.	1.8	96
17	Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e57-e67.	10.7	95
18	Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The, 2021, 22, e45-e56.	10.7	91

#	Article	IF	CITATIONS
19	Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncology, The, 2019, 20, e29-e41.	10.7	90
20	Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget, 2015, 6, 7232-7243.	1.8	85
21	Congenital mesoblastic nephroma 50 years after its recognition: A narrative review. Pediatric Blood and Cancer, 2017, 64, e26437.	1.5	84
22	miR-9 is a tumor suppressor in pediatric AML with t(8;21). Leukemia, 2014, 28, 1022-1032.	7.2	72
23	Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. European Journal of Cancer, 2016, 69, 77-85.	2.8	72
24	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood, 2015, 125, 2311-2313.	1.4	60
25	Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors. PLoS ONE, 2012, 7, e52237.	2.5	59
26	Longitudinal development of cancerâ€related fatigue and physical activity in childhood cancer patients. Pediatric Blood and Cancer, 2019, 66, e27949.	1.5	58
27	Management and treatment of osteonecrosis in children and adolescents with acute lymphoblastic leukemia. Haematologica, 2014, 99, 430-436.	3.5	55
28	Molecular basis of juvenile myelomonocytic leukemia. Haematologica, 2010, 95, 179-182.	3.5	53
29	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. Blood, 2016, 127, 1163-1172.	1.4	48
30	Long-term effects of childhood cancer treatment on hormonal and ultrasound markers of ovarian reserve. Human Reproduction, 2018, 33, 1474-1488.	0.9	48
31	Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors. Critical Reviews in Oncology/Hematology, 2019, 133, 129-141.	4.4	44
32	Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer. PLoS ONE, 2012, 7, e43269.	2.5	44
33	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	3.5	43
34	A comparison of genotyping arrays. European Journal of Human Genetics, 2021, 29, 1611-1624.	2.8	43
35	The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. European Journal of Endocrinology, 2018, 178, 11-22.	3.7	41
36	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European Journal of Cancer, 2018, 103, 227-237.	2.8	41

#	Article	IF	CITATIONS
37	Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours. Nature Communications, 2021, 12, 1407.	12.8	41
38	Effects of a combined physical and psychosocial training for children with cancer: a randomized controlled trial. BMC Cancer, 2018, 18, 1289.	2.6	37
39	Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, The. 2021. 22. e68-e80.	10.7	37
40	The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia. Haematologica, 2015, 100, 62-69.	3.5	36
41	Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatric Hematology and Oncology, 2017, 34, 120-129.	0.8	35
42	<i>RASA4</i> undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics, 2014, 9, 1252-1260.	2.7	34
43	Renal cell carcinoma in young FH mutation carriers: case series and review of the literature. Familial Cancer, 2020, 19, 55-63.	1.9	32
44	The influence of genetic variation on late toxicities in childhood cancer survivors: A review. Critical Reviews in Oncology/Hematology, 2018, 126, 154-167.	4.4	31
45	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	2.8	31
46	Characteristics and Outcome of Children with Renal Cell Carcinoma: A Narrative Review. Cancers, 2020, 12, 1776.	3.7	29
47	A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. BMC Cancer, 2012, 12, 363.	2.6	28
48	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics Journal, 2020, 20, 294-305.	2.0	28
49	Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature. Cancers, 2021, 13, 3142.	3.7	27
50	Single cell derived mRNA signals across human kidney tumors. Nature Communications, 2021, 12, 3896.	12.8	27
51	Decreased ovarian function is associated with obesity in very long-term female survivors of childhood cancer. European Journal of Endocrinology, 2013, 168, 905-912.	3.7	26
52	Long-Term Quality of Life in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1218-1226.	3.6	26
53	Reproductive intentions and use of reproductive health care among female survivors of childhood cancer. Human Reproduction, 2018, 33, 1167-1174.	0.9	25
54	Renal Tumors of Childhood—A Histopathologic Pattern-Based Diagnostic Approach. Cancers, 2020, 12, 729.	3.7	25

#	Article	IF	CITATIONS
55	Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors. Cell Reports, 2021, 36, 109568.	6.4	25
56	Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. European Journal of Cancer, 2021, 153, 51-63.	2.8	25
57	Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia. Leukemia Research, 2013, 37, 367-371.	0.8	24
58	Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors. European Journal of Cancer, 2013, 49, 668-675.	2.8	24
59	Evaluation of needle biopsy as a potential risk factor for local recurrence of Wilms tumour in the SIOP WT 2001 trial. European Journal of Cancer, 2019, 116, 13-20.	2.8	24
60	Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). Human Reproduction, 2021, 36, 1561-1573.	0.9	20
61	Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma. European Journal of Cancer, 2012, 48, 1159-1166.	2.8	18
62	LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. Haematologica, 2016, 101, e240-e244.	3.5	18
63	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 2020, 12, 1789.	3.7	18
64	<scp>MRI</scp> Characteristics of Pediatric Renal Tumors: A <scp>SIOPâ€RTSG</scp> Radiology Panel Delphi Study. Journal of Magnetic Resonance Imaging, 2022, 55, 543-552.	3.4	18
65	Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. Thyroid, 2017, 27, 1481-1489.	4.5	16
66	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. JAMA Oncology, 2021, 7, 1550.	7.1	14
67	Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Research Protocols, 2018, 7, e10824.	1.0	14
68	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer, 2018, 18, 930.	2.6	13
69	The long non-coding RNA landscape in juvenile myelomonocytic leukemia. Haematologica, 2018, 103, e501-e504.	3.5	13
70	Nutritional Preconditioning in Cancer Treatment in Relation to DNA Damage and Aging. Annual Review of Cancer Biology, 2021, 5, 161-179.	4.5	13
71	Intracranial relapse in Wilms tumor patients. Pediatric Blood and Cancer, 2004, 43, 737-741.	1.5	12
72	Tinnitus during and after childhood cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2019, 135, 1-7.	4.4	12

#	Article	IF	CITATIONS
73	Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology: A Randomized Controlled Trial Comparing Push Injections with One-Hour Infusions (The VINCA Trial). Cancers, 2020, 12, 3745.	3.7	12
74	Diagnosing metabolic syndrome in craniopharyngioma patients: body composition versus BMI. European Journal of Endocrinology, 2019, 181, 173-183.	3.7	12
75	Cost-effectiveness of a combined physical exercise and psychosocial training intervention for children with cancer: Results from the quality of life in motion study. European Journal of Cancer Care, 2017, 26, e12586.	1.5	11
76	Clinical and Molecular Characteristics and Outcome of Cystic Partially Differentiated Nephroblastoma and Cystic Nephroma: A Narrative Review of the Literature. Cancers, 2021, 13, 997.	3.7	11
77	Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy. Cancers, 2021, 13, 1214.	3.7	11
78	Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review. Obesity Reviews, 2021, 22, e13312.	6.5	11
79	Classification of pediatric acute myeloid leukemia based on miRNA expression profiles. Oncotarget, 2017, 8, 33078-33085.	1.8	11
80	Human Telomere Disease Due to Disruption of the CCAAT Box of the TERC Promoter. Blood, 2011, 118, 2405-2405.	1.4	11
81	Healthâ€related fitness in very longâ€ŧerm survivors of childhood cancer: A crossâ€sectional study. Pediatric Blood and Cancer, 2018, 65, e26907.	1.5	10
82	Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors. Clinical and Translational Radiation Oncology, 2021, 29, 20-26.	1.7	10
83	Bariatric Surgery for Hypothalamic Obesity in Craniopharyngioma Patients: A Retrospective, Matched Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4734-e4745.	3.6	10
84	Metabolic syndrome detection with biomarkers in childhood cancer survivors. Endocrine Connections, 2020, 9, 676-686.	1.9	10
85	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	1.0	10
86	Long-Term Effects of Childhood Cancer Treatment on Dentition and Oral Health: A Dentist Survey Study from the DCCSS LATER 2 Study. Cancers, 2021, 13, 5264.	3.7	10
87	Characteristics and outcome of children with renal tumors in the Netherlands: The first five-year's experience of national centralization. PLoS ONE, 2022, 17, e0261729.	2.5	10
88	Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR Research Protocols, 2021, 10, e21851.	1.0	9
89	How we approach paediatric renal tumour core needle biopsy in the setting of preoperative chemotherapy: A Review from the SIOP Renal Tumour Study Group. Pediatric Blood and Cancer, 2022, 69, e29702.	1.5	9
90	TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. Npj Precision Oncology, 2021, 5, 64.	5.4	8

#	Article	IF	CITATIONS
91	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers, 2021, 13, 4598.	3.7	8
92	Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design. BMC Pediatrics, 2021, 21, 427.	1.7	8
93	Effect of Web-Based Versus Paper-Based Questionnaires and Follow-Up Strategies on Participation Rates of Dutch Childhood Cancer Survivors: A Randomized Controlled Trial. JMIR Cancer, 2015, 1, e11.	2.4	8
94	Renal cell carcinoma in children and adolescents: a retrospective study of a French–Italian series of 93 cases. Histopathology, 2022, 80, 928-945.	2.9	8
95	Outcome of Stage IV Completely Necrotic Wilms Tumour and Local Stage III Treated According to the SIOP 2001 Protocol. Cancers, 2021, 13, 976.	3.7	6
96	Bilateral Renal Tumors in Children: The First 5 Years' Experience of National Centralization in The Netherlands and a Narrative Review of the Literature. Journal of Clinical Medicine, 2021, 10, 5558.	2.4	6
97	Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort. Cancer Causes and Control, 2019, 30, 909-922.	1.8	5
98	Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors. Neuro-Oncology Advances, 2021, 3, vdab161.	0.7	5
99	Oncofertility Perspectives for Girls with Cancer. Journal of Pediatric and Adolescent Gynecology, 2022, 35, 523-526.	0.7	5
100	Dexamethasone-Induced Sarcopenia and Physical Frailty in Children With Acute Lymphoblastic Leukemia: Protocol for a Prospective Cohort Study. JMIR Research Protocols, 2022, 11, e33517.	1.0	5
101	Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms. Cancer Discovery, 0, , OF1-OF14.	9.4	5
102	Interobserver variability between experienced and inexperienced observers in the histopathological analysis of Wilms tumors: a pilot study for future algorithmic approach. Diagnostic Pathology, 2021, 16, 77.	2.0	4
103	Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy. Cancers, 2022, 14, 943.	3.7	4
104	Fractures, Bone Mineral Density, and Final Height in Craniopharyngioma Patients with a Follow-up of 16 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1397-e1407.	3.6	3
105	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. Haematologica, 2022, 107, 759-764.	3.5	3
106	Psychosocial developmental milestones of young adult survivors of childhood cancer. Supportive Care in Cancer, 2022, 30, 6839-6849.	2.2	3
107	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	1.0	2
108	Body Composition and Bone Mineral Density in Craniopharyngioma Patients: A Longitudinal Study Over 10 Years. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4626-e4637.	3.6	2

#	Article	IF	CITATIONS
109	Metabolic Syndrome Parameters, Determinants, and Biomarkers in Adult Survivors of Childhood Cancer: Protocol for the Dutch Childhood Cancer Survivor Study on Metabolic Syndrome (Dutch) Tj ETQq1 1 0.7	'84B04 rgB	T ‡Overloc R
110	NF1 Microdeletions in Pediatric MLL-Rearranged AML and T-ALL: A Novel Mechanism for RAS Activation Blood, 2007, 110, 757-757.	1.4	2
111	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias Blood, 2006, 108, 734-734.	1.4	2
112	Comment on "Acute lymphoblastic leukemia and adiponcosis" by M. Bifulco and AM Malfitano. Haematologica, 2015, 100, e432-e433.	3.5	1
113	Nucleophosmin Gene Mutations Identify a Favorable Risk Group in Childhood Acute Myeloid Leukemia with a Normal Karyotype Blood, 2007, 110, 366-366.	1.4	1
114	Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia Blood, 2008, 112, 1509-1509.	1.4	1
115	Frailty in longâ€ŧerm Dutch adult survivors of childhood acute myeloid leukaemia, neuroblastoma, and Wilms' tumour. JCSM Clinical Reports, 2021, 6, 3-10.	1.3	1
116	Hearing and Other Neurologic Problems. Pediatric Clinics of North America, 2020, 67, 1219-1235.	1.8	0
117	Recent perspectives on the association between osteonecrosis and bone mineral density decline in childhood acute lymphoblastic leukemia. Faculty Reviews, 2021, 10, 57.	3.9	0
118	Cytogenetics in Pediatric MDS - Data of the EWOG-MDS 98 Study Blood, 2005, 106, 4914-4914.	1.4	0
119	No Evidence for Constitutively Activated FLT3 in Juvenile Myelo-Monocytic Leukemia Blood, 2005, 106, 4915-4915.	1.4	0
120	Differences in Cyto- and Molecular Genetic Abnormalities between Children <2 Years and Older Children with Acute Myeloid Leukemia Blood, 2007, 110, 1830-1830.	1.4	0
121	Low Frequency of MLL-PTD Detected in Pediatric Acute Myeloid Leukemia Using MLPA Screening Blood, 2008, 112, 1512-1512.	1.4	0
122	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	1.4	0
123	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
124	Ototoxicity After Childhood Cancer. , 2021, , 27-48.		0
125	Overweight in the Dutch National Cohort of Long-Term Survivors of Childhood Cancer. Blood, 2021, 138, 3054-3054.	1.4	0
126	A Study on Prevalence and Determinants of Ototoxicity During Treatment of Childhood Cancer (SOUND): Protocol for a Prospective Study. JMIR Research Protocols, 2022, 11, e34297.	1.0	0

#	Article	IF	CITATIONS
127	Long-Term Tubular Dysfunction in Childhood Cancer Survivors; DCCSS-LATER 2 Renal Study. Cancers, 2022, 14, 2754.	3.7	0